If GLP-1 is banned, I will stop using it before competition periods
The Packaging Challenges Facing GLP-1 Therapies In many cases, manufacturers supply GLP1 products as primary packaged units without: final labelling and serialization retail-ready secondary packaging integrated accessories or patient-use components region-specific configurations This creates a critical gap between manufacturing and commercialization
Its responsible for several metabolic functions, including energy production and cellular repair
As patients dont feel like eating, theyre not prompted to hydrate regularly either, explains Dr Debra Marcos, who is both medical director at Weight Medics and a specialist in gastroenterology, clinical nutrition and GLP-1 therapy
Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
